For the year ending 2025-12-31, BCAX had -$393,026K decrease in cash & cash equivalents over the period. -$107,114K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -137,950 |
| Stock-based compensation | 15,006 |
| Depreciation | 105 |
| Non-cash lease expense | 895 |
| Net amortization of premiums and discounts on marketable securities | -301 |
| Prepaid expenses and other assets | -5,281 |
| Accounts payable and accrued expenses-Nonrelated Party | 7,657 |
| Accounts payable and accrued expenses-Related Party | 2,803 |
| Operating lease liabilities | -932 |
| Net cash used in operating activities | -106,834 |
| Purchases of marketable securities | 318,173 |
| Purchase of property and equipment | 280 |
| Proceeds from sale of property and equipment | 0 |
| Net cash used in investing activities | -318,453 |
| Proceeds from issuance on common stock, net of issuance costs | 29,498 |
| Proceeds from exercise of options | 2,763 |
| Net cash provided by financing activities | 32,261 |
| Net increase (decrease) in cash and cash equivalents | -393,026 |
| Cash and cash equivalents at beginning of period | 489,711 |
| Cash and cash equivalents at end of period | 96,685 |
Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics Inc. (BCAX)